Industry experts have always known that there is a significant gap between the manufacturing cost and sales price of popular GLP-1 drugs, which are effective for both weight loss and diabetes management. Now they know also know how wide that gap really is.
Ozempic from Novo Nordisk, which sells for nearly $1,000 a month, can be manufactured for less than $5, according to a study from researchers at Yale University, King's College Hospital in London and the nonprofit Doctors Without Borders. It generally can be produced for less than various forms of insulin.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
